Breast cancer gene expression analysis: The case for dynamic profiling

Advances in Experimental Medicine and Biology

Volumn 532, Issue , 2003, Pages 223-234

  Ellis, Matthew J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BIOLOGICAL MARKER; ESTROGEN RECEPTOR; LETROZOLE; MESSENGER RNA; TAMOXIFEN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER RESEARCH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG TOLERABILITY; FOLLOW UP; GENE AMPLIFICATION; GENE CLUSTER; GENE EXPRESSION; GENE MUTATION; HOMEOSTASIS; HORMONAL THERAPY; HUMAN; HUMAN GENOME; LYMPHOMA; METASTASIS; NEEDLE BIOPSY; NUCLEOTIDE SEQUENCE; ONCOGENE NEU; ONCOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SOMATIC MUTATION; STATISTICAL MODEL; TREATMENT OUTCOME; TUMOR BIOPSY;

EID: 0141868958     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0081-0_18     Document Type: Conference Paper

References (18)

1. van't Veer, L. J., Dal, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van de Kooy, K., Marton, M. J., Witteveen, A. T., Schreber, G. J., Kerkhoven, R. M., Roberts, C., Linsley, P. S., Bernards, R., and Friend, S. F. Gene expression profiling predicts clinical outcome of breast cancer, Nature. 415: 530-536, 2002.
2. Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Thorsen, T., Quist, H., Matese, J. C., Brown, P. O., Botstein, D., Eystein Lonning, P., and Borresen-Dale, A. L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A. 98: 10869-74., 2001.
3. Shipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., Ray, T. S., Koval, M. A., Last, K. W., Norton, A., Lister, T. A., Mesirov, J., Neuberg, D. S., Lander, E. S., Aster, J. C., and Golub, T. R. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning, Nat Med. 8: 68-74., 2002.
4. Clark, G. M. and McGuire, W. L. Steroid receptors and other prognostic factors in primary breast cancer, Semin Oncol. 15: 20-5, 1988.
5. Foekens, J. A., Portengen, H., Look, M. P., van Putten, W. L., Thirion, B., Bontenbal, M., and Klijn, J. G. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer, Br J Cancer. 70: 1217-23, 1994.
6. Schwartz, L. H., Koerner, F. C., Edgerton, S. M., Sawicka, J. M., Rio, M. C., Bellocq, J. P., Chambon, P., and Thor, A. D. pS2 expression and response to hormonal therapy in patients with advanced breast cancer, Cancer Res. 51: 624-8, 1991.
7. Hu, J. C. C. and Mokbel, K. Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer?, Eur J Surg Oncol. 27: 335-337, 2001.
8. Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Janicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., Quebe-Fehling, E., and Borgs, M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor- positive primary breast cancer: evidence from a phase III randomized trial, J Clin Oncol. 19: 3808-16., 2001.
9. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group, Lancet. 352: 930-42, 1998.
10. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group, Lancet. 351. 1451-67, 1998.
11. Fisher, B., Dignam, J., Wolmark, N., DeCillis, A., Emir, B., Wickerham, D. L., Bryant, J., Dimitrov, N. V., Abramson, N., Atkins, J. N., Shibata, H., Deschenes, L., and Margolese, R. G. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor- positive breast cancer, J Natl Cancer Inst. 89: 1673-82, 1997.
12. Albain, K. S., Green, S., Ravdin, P., Cobau, C., Levine, J. E., Ingle, J. N., Pritchard, K., Schneider, M., Abeloff, M. D., Norton, L., Lew, D., Martino, S., and Osborne, C. K. Overall survival after cyclophosphamide, Adriamycin, 5FU and Tamoxifen (CAFT) is superiour to T alone in postmenopausal, receptor (+), Node (+) Breast cancer: New findings from Phase III Southwest Oncology Group Intergroup Trial S8814 (INT-0100) (Abstract 94), Proc ASCO. 20: 24a, 2001.
13. West, M., Blanchette, C., Dressman, H., Huang, E., Ishida, S., Spang, R., Zuzan, H., Olson, J. A., Jr., Marks, J. R., and Nevins, J. R. Predicting the clinical status of human breast cancer by using gene expression profiles, Proc Natl Acad Sci U S A. 98: 11462-7., 2001.
14. Dressman, M. A., Walz, T. M., Barnes, L., Buchholtz, S., Kwon, I., Lavedan, C., Ellis, M. J., and M.H., P. Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies, The Pharmacogenomics Journal. 1: 135-141, 2001.
15. Eiermann, W., Paepke, S., Appffelstaedt, J., Llombard-Cussac, A., Eremin, J., Vinholes, J., Mauriac, L., Ellis, M., Lassus, M., Chaudrai, H. A., Dugan, M., Borgs, M., and Semiglazov, V. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study., Annals Oncol. 12: 1-6, 2001.
16. Ellis, M. J. Neoadjuvant endocrine therapy for Breast Cancer: Medical perspectives., Clin Cancer Res. 7: 4388s-4391s, 2001.
17. Ellis, M. J. Preoperative endocrine therapy for older women with breast cancer: renewed interest in an old idea., Cancer Control. 7: 557-62, 2000.
18. Ellis, M.J., Rosen, E. Dressman H and Marks J. Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: Pretreatment determinants of response and on-treatment effect. J Steroid Chemistry and Mol Biol. In Press.